Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer

To compare the clinical efficacy and adverse reactions associated with nano-albumin paclitaxel combined with cisplatin and traditional paclitaxel combined with cisplatin for the treatment of non-small cell lung cancer. From December 2016 to August 2019, 78 patients with non-small cell lung cancer in our hospital were randomly allocated into either the observation group (n = 39) or the control group (n = 39). The observation group was treated with nano-albumin combined with cisplatin, and the control group was treated with traditional paclitaxel combined with platinum chemotherapy. After four cycles of treatment, the clinical efficacy and adverse reactions for the two groups were statistically analyzed. Before treatment, there was no statistically significant difference in age, sex, tumor type, and ECOG score between the two groups. After four cycles of treatment, the disease control rate in the observation group was 79.49%, which was significantly higher than that in the control group (38.46%, P <0.05), and the occurrence of myelosuppression, nausea, vomiting, and hyperglycemia in the observation group was significantly lower than that in the control group (P <0.05). Compared with the traditional paclitaxel combined with platinum chemotherapy regimen, the nanoalbumin combined with paclitaxel regimen had significant clinical effect and the adverse reactions were significantly reduced. Thus, it can be considered effective and safe and is suitable for clinical promotion.